GLP-1 Sleep Apnea Pipeline: Which Obesity Drugs Matter?

Which Obesity Drugs Are Approved for Sleep Apnea? Is Ozempic One of Them?

One. As of May 23, 2026, Zepbound (tirzepatide) by Eli Lilly is the only obesity drug with an FDA-approved indication for obstructive sleep apnea. The FDA granted the approval on December 20, 2024, for the treatment of moderate-to-severe OSA in adults with obesity. This made Zepbound the first prescription medicine ever approved specifically for OSA.

Before this approval, the standard of care for OSA was continuous positive airway pressure (CPAP) therapy. No prescription drug had demonstrated sufficient efficacy in a controlled trial to earn an FDA indication. Zepbound changed that.

No other GLP-1 receptor agonist, dual agonist, or triple agonist has an FDA-approved OSA indication. Semaglutide (Wegovy/Ozempic) is not approved for sleep apnea. CagriSema and survodutide have no OSA-specific trial data. Retatrutide is actively studying the question on two tracks — TRIUMPH-3 with OSA as a pre-specified endpoint, and a dedicated Phase 3 study in moderate-to-severe obstructive sleep apnea disclosed in Lilly’s May 2026 pipeline update — but has not yet reported results.

What Did the SURMOUNT-OSA Trial Show?

The SURMOUNT-OSA trial was a randomized, double-blind, placebo-controlled Phase 3 study evaluating tirzepatide in adults with moderate-to-severe obstructive sleep apnea and obesity, typically reflected in elevated body mass index. The trial had two arms: one with patients not using CPAP at baseline, and one with patients using CPAP.

The headline results were significant. Tirzepatide produced approximately 18% body weight loss and reduced the apnea-hypopnea index (AHI) by 51–52% versus baseline. AHI is the primary clinical measure of sleep apnea severity — it counts the number of apnea and hypopnea events per hour of sleep and is also used to track OSA severity over time.

Perhaps more notable: 42–50% of patients achieved disease remission, defined as an AHI below 5 events per hour. An AHI below 5 is clinically considered normal — meaning nearly half the patients in the trial no longer met the diagnostic threshold for sleep apnea, and reductions in AHI generally help improve symptoms.

These results were strong enough for the FDA to grant a new indication — the first time any drug had cleared that bar for OSA.

A pre-specified secondary analysis published in Nature Medicine on January 15, 2026 added a layer the original readout had only hinted at. Tirzepatide produced greater alleviation of cardiometabolic risk factors than placebo, and mediation analysis showed that improvements in OSA-specific metrics independently contributed to drops in hsCRP, HOMA-IR, and triglycerides over and above the weight-loss effect alone. The practical reading: treating the airway and the metabolic disease together is what captures the full cardiometabolic benefit — neither alone reproduces the combination. Source: Nature Medicine secondary analysis of SURMOUNT-OSA, PMID 41540105.

Is Retatrutide Being Studied for Sleep Apnea?

Yes — on two tracks. Eli Lilly’s TRIUMPH-3 Phase 3 trial includes obstructive sleep apnea as a pre-specified endpoint, designed from the start to measure OSA outcomes. In addition, Lilly’s May 2026 pipeline update discloses an active Phase 3 study of retatrutide in moderate-to-severe obstructive sleep apnea as an expanded standalone indication, separate from the broader TRIUMPH obesity program.

As of May 2026, no OSA-specific results have been reported from either study. The TRIUMPH-3 readout is expected in 2026. Given retatrutide’s triple-agonist mechanism (GLP-1 + GIP + glucagon receptor), there is scientific interest in whether acting across multiple hormone pathways adds benefits beyond what tirzepatide, one of the newer dual agonist drugs, achieves for OSA. Our retatrutide vs tirzepatide vs CagriSema comparison details how these mechanisms diverge across efficacy endpoints.

In Phase 2, retatrutide demonstrated up to 24.2% weight loss at 48 weeks. The December 2025 TRIUMPH-4 Phase 3 readout reported 28.7% at 12 mg over 68 weeks, and on May 21, 2026 the pivotal TRIUMPH-1 obesity trial reported 28.3% mean weight loss at 80 weeks on 12 mg (n=2,339) and up to 30.3% at 104 weeks in a BMI ≥35 extension — substantially higher than tirzepatide’s ~18% in SURMOUNT-OSA. If TRIUMPH-3 or the dedicated OSA Phase 3 study show proportionally greater AHI reduction, retatrutide could become the second obesity drug approved for OSA and potentially the most effective pharmacological option available. For retatrutide titration protocols and dosing schedules used in the TRIUMPH program, see the retatrutide dosage guide. For a detailed analysis of retatrutide adverse events including the dysesthesia signal, see our retatrutide side effects profile.

Why Do Weight Loss Medications Improve Sleep Apnea?

Approximately 70% of patients with obstructive sleep apnea have excess weight or obesity, and obesity is the primary risk factor for sleep apnea, driving roughly 60% of cases. The connection is mechanical: excess adipose tissue around the upper airway increases pharyngeal collapsibility during sleep, leading to repeated airway obstruction — the hallmark of OSA.

Even a 10% weight gain can raise the risk of developing sleep apnea by about six-fold.

Clinical data consistently shows that 10–15% weight reduction can significantly reduce AHI scores, may lead to remission in some mild-to-moderate cases, and GLP-1 agonists are being studied as a way to help patients achieve it. The mechanism is straightforward: reducing fat deposits around the pharynx and tongue base decreases the mechanical load on the airway, reducing the frequency and severity of obstructive events and helping improve OSA symptoms. GLP-1 medications such as semaglutide and tirzepatide can also produce significant weight loss linked to lower AHI and symptom improvement.

This is why obesity drugs that produce meaningful weight loss are better understood as one treatment option for treating obstructive sleep apnea indirectly, rather than as direct cures, with possible benefit in some patients with metabolic disorders also extending through lower systemic inflammation. However, the relationship is not perfectly linear — some patients with significant weight loss still have residual OSA, which is why the FDA requires controlled trial evidence rather than extrapolating from weight-loss data alone. For a wider look at the obesity drug landscape, see our best obesity drug 2026 comparison.

PAP therapy, including continuous positive airway pressure (CPAP), remains the standard of care, but real-world adherence is approximately 50%. Many patients cannot tolerate the device, struggle with a CPAP machine, use it inconsistently, or abandon it entirely. Patients should not stop CPAP or other positive airway pressure treatment without medical supervision. Weight loss that reduces airway obstruction may lessen poor sleep and improve deep sleep. This adherence gap is what makes pharmacological alternatives like Zepbound clinically significant — not as a CPAP replacement, but as a complement or alternative for patients who cannot maintain CPAP therapy.

2026 Pooled Estimate — GLP-1 Class Effect on AHI

Beyond any single trial, an April 24, 2026 meta-analysis in Sleep & Breathing pooled 4 randomised controlled trials of GLP-1-based therapies in obstructive sleep apnea. The pooled estimate was a mean AHI reduction of −13.89 events/hour (95% CI −22.86 to −4.92, p<0.01), alongside 4–6 mmHg reductions in systolic blood pressure. This is the first class-level synthesis of the OSA-and-incretin literature, and it puts a number on the effect across studies rather than within a single program.

The pooled figure sits below SURMOUNT-OSA's headline 51–52% relative AHI reduction because it averages across trials, doses, and baseline severities — and an absolute events/hour change is a different metric from a relative percentage. Read together, the single-trial and pooled data both point in the same direction: meaningful AHI reduction tracking weight loss, plus a blood-pressure co-benefit. These are research findings on prescription medicines, reported here as scientific context — Remy Peptides supplies research-grade peptides for in-vitro laboratory use only.

Do GLP-1 Drugs Improve Sleep Apnea Without an OSA Approval?

Some observational and retrospective data suggest that GLP-1 receptor agonists may improve sleep apnea markers secondary to weight loss. This is mechanistically plausible — any drug that produces 10–15%+ weight loss should reduce AHI in obese patients with OSA.

However, observational data is not the same as a controlled trial with an OSA-specific primary endpoint. The FDA approved Zepbound for OSA based on SURMOUNT-OSA — a purpose-designed, randomized, placebo-controlled study that measured AHI reduction as a primary outcome. No other GLP-1 agonist has this level of evidence for OSA.

Semaglutide (Wegovy/Ozempic) is one of the most commonly prescribed weight loss medications for obesity, but Novo Nordisk has not announced an OSA-specific clinical trial. Without controlled data, any claims about semaglutide treating sleep apnea are extrapolation, not evidence. It does not have FDA approval for treating OSA specifically and should not be presented as an approved OSA treatment. Healthcare providers may observe improvement in some OSA patients taking semaglutide, but this does not constitute an approved indication. For a comparison of adverse event profiles across these compounds, see our Ozempic vs Mounjaro vs Wegovy side effects review.

What Should Researchers Watch Next?

Three developments will shape the OSA treatment landscape in 2026 and beyond:

1. TRIUMPH-3 + dedicated OSA Phase 3 readouts for retatrutide. Lilly is running both TRIUMPH-3 (OSA as a pre-specified endpoint) and, per its May 2026 pipeline update, a dedicated Phase 3 study in moderate-to-severe obstructive sleep apnea. With TRIUMPH-1 already at 28.3% mean weight loss at 80 weeks, positive OSA data would position retatrutide as the second FDA-approved drug for sleep apnea — and potentially the most effective, given its superior weight-loss profile versus tirzepatide. Readouts are expected in 2026.

2. Real-world Zepbound OSA data. Post-approval studies and real-world evidence will clarify how Zepbound performs outside controlled trial conditions — particularly on CPAP discontinuation rates, long-term AHI durability, and changes in OSA severity over time.

3. Whether competitors pursue OSA indications. Novo Nordisk (semaglutide), Amgen, and Zealand/Roche have not announced OSA-focused trials, but semaglutide and peers can be viewed more broadly as anti-obesity medications being evaluated for possible future OSA programs. If TRIUMPH-3 is positive, competitive pressure may drive additional OSA programs. Until then, Zepbound remains the only approved pharmacological option. Explore the full landscape of anti-obesity medications in our best obesity drug 2026 guide.

Weight management will remain central to future OSA research even as more drugs are studied.